TN 7 (08-12)

DI 23022.700 Child Non-Hodgkin Lymphoma--recurrent

COMPASSIONATE ALLOWANCE INFORMATION

CHILD NON-HODGKIN LYMPHOMA

ALTERNATE NAMES

Non-Hodgkin Lymphoma; Lymphoblastic Lymphoma; Diffuse Large B-cell Lymphoma; B-cell Lymphoma; T-cell Lymphoma; Peripheral T-cell Lymphoma; Follicular Lymphoma; Burkitt Lymphoma; Anaplastic Large Cell Lymphoma

DESCRIPTION

Non-Hodgkin lymphoma (NHL) is cancer in the lymphatic system. Lymphomas are cancer cells that start in the lymphatic systems. When cancer cells get into the lymphatic system, the cancerous cells can also spread to other organs and tissues in the body. Child Non-Hodgkin Lymphoma is the third most common cancer in children. Child non-Hodgkin Lymphoma that is recurrent after initial anti- neoplastic treatment occurs when the cancer returns after treatment. Most childhood NHLs can be classified as one of the following four types:

  • Burkitt lymphoma (BL), or small noncleaved cell lymphoma (SNCCL)

  • Lymphoblastic lymphoma (LL)

  • Diffuse large B-cell lymphoma (DLBCL)

  • Anaplastic large cell lymphoma (ALDL)

Signs of childhood non-Hodgkin lymphoma may include breathing problems and swollen lymph nodes. These children may also exhibit symptoms of breathing difficulties, wheezing, coughing, swelling of the head, neck, upper body or arms, experience difficulties swallowing, have painless swelling of the lymph nodes in the neck, underarm, stomach or groin, experience unexplained weight loss, night sweats, and fever.

DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM CODING

Diagnostic testing: Diagnostic testing for child NHL includes physical examination, blood and urine tests, lymph node biopsy, bone marrow aspirate and biopsy, lumbar puncture, removal of fluid from chest or abdomen for testing, X-rays, ultrasound, radionuclide bone scan, MRI, CT, and PET scan.

Physical findings: Childhood NHL may cause many different signs and symptoms, depending on the location of the tumors. NHL that grows close to the surface of the body (sides of the neck, underarm area above the collarbone or in the groin area) may have enlarged nodes that are seen, or felt, as lumps under the skin. Lymphoma that is in the abdomen area will cause it to become swollen and tender. NHL that starts in the thymus gland or lymph nodes of the chest or near the windpipe (trachea) may cause swelling and a bluish-red skin color.

ICD-9: 200.2 (Burkitt lymphoma); 200.5 (Primary CNS lymphoma); 200.6 (Anaplastic large cell lymphoma); 200.7 (Large cell lymphoma); 202.0 (Follicular or lymphocytic lymphoma); 202.7 (Peripheral T-cell lymphoma); 202.8 (Malignant lymphoma NOS)

ONSET AND PROGRESSION

NHL is usually a disease of rapid onset and progression. Although the prognosis greatly depends on histology, extent of the disease, presence or absence of metastasis; the child’s age; and response to therapy, the majority of children with newly diagnosed NHL are considered to have an excellent prognosis. Children with recurrent NHL have a less favorable prognosis and require longer treatment. If the child does not respond to chemotherapy drugs, the disease can cause rapid death.

TREATMENT

By the time a child is diagnosed with NHL, the lymphoma has spread to other parts of the body. Most children with NHL are treated with chemotherapy. Chemotherapy is the most important treatment for children with NHL because chemotherapy can reach all parts of the body and kill lymphoma cells wherever they may be. It is common to use a combination of drugs and treatment, including intrathecal therapy (injection of chemotherapy into the spinal fluid), that may last a number of months or years.

SUGGESTED PROGRAMMATIC ASSESSMENT*

Suggested MER for evaluation: The adjudicator needs medical evidence from treating sources and hospitals. It should include clinical examination, imaging tests, biopsies, pathology reports, surgical procedures, pertinent treatment records, and up-to-date progress notes.

Suggested Listings for Evaluation:

DETERMINATION

LISTING

REMARKS

Meets Listing

113.05A

Recurrent pediatric non-Hodgkin lymphoma meets listing 113.05A upon confirmed diagnosis, regardless of effectiveness of treatment.

NOTE: Evaluate pediatric T-cell lymphoblastic lymphoma under listing 113.06.

Medical Equals

  

* Adjudicators may, at their discretion, use the Medical Evidence of Record or Listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.


To Link to this section - Use this URL:
http://policy.ssa.gov/poms.nsf/lnx/0423022700
DI 23022.700 - Child Non-Hodgkin Lymphoma--recurrent - 08/10/2012
Batch run: 08/10/2012
Rev:08/10/2012